Hypertension: Beta-Blocker Pharmacokinetics

Hypertension: Beta-Blocker Pharmacokinetics

HYPERTENSION: BETA-BLOCKER PHARMACOKINETICS
Generic Brand Cardio-
selec
tivity
ISA MSA Lipid
Solu–
bility
Protein
Bound
(%)
Metab–
olism
Elimination Vaso-
dila–
tory
acebutolol — ✓ ✓ ✓ Low 26 Hepatic Bile, renal
atenolol Tenormin ✓ Low 6–16 Renal
(primarily), fecal
betaxolol — ✓ Low 50 Hepatic Renal ✓
bisoprolol — ✓ Low to Medium ~30 Hepatic Renal, fecal
carvedilol* Coreg High 98 Hepatic (CYP2C9, CYP2D6) Fecal
(primarily), renal
✓
Coreg CR
labetalol* Trandate ✓ Medium ~50 Hepatic (glucuron–
idation)
Renal, fecal ✓
meto–
prolol
Kapspargo Sprinkle ✓ Medium 12 Hepatic (CYP2D6) Renal
Lopressor
Toprol-XL
nadolol Corgard Low 30 Renal
nebivolol Bystolic ✓ Low 98 Hepatic Renal, fecal ✓
pindolol — ✓ Medium 40 Hepatic Renal
propran–
olol
— ✓ High 90 Hepatic (CYP2D6, CYP1A2) Renal
Inderal LA
InnoPran
 XL
timolol — Medium <10 Hepatic Renal
NOTES

Cardioselective products are less likely to cause bronchospasm, peripheral vasoconstriction, or hypoglycemia than non-cardioselective ones.

ISA: Intrinsic sympathomimetic activity may partially reduce the cardiac depressant and bronchoconstricting effects of β-blockade.

MSA: Membrane stabilizing activity may contribute to the clinical management of cardiac arrhythmias.

* These have both α– and β-blocking activity.

Lipid solubility determines how readily the drug passes through the blood brain barrier and possibly the placenta. Those drugs that have high lipid solubility pass through more readily than those agents with low lipid solubility. The incidence of CNS side effects may be higher in products with higher lipid solubility.

(Rev. 10/2023)